Iovance Biotherapeutics, a biotechnology company developing cancer immunotherapies, and MaSTherCell S.A., a cell therapy CDMO, have entered into a new three-year manufacturing services agreement under which MaSTherCell will manufacture TIL for Iovance’s late-stage clinical trials at its commercial-ready cGMP manufacturing suites.    “We are pleased to be expanding our clinical and manufacturing capacity in Europe through this new collaboration with MaSTherCell. We have been dosing patients wit...